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AbsTrACT
Strong surgical systems are necessary to prevent 
premature death and avoidable disability from surgical 
conditions. The epidemiological transition, which has 
led to a rising burden of non- communicable diseases 
and injuries worldwide, will increase the demand for 
surgical assessment and care as a definitive healthcare 
intervention. Yet, 5 billion people lack access to timely, 
affordable and safe surgical and anaesthesia care, with 
the unmet demand affecting predominantly low- income 
and middle- income countries (LMICs). Rapid surgical care 
scale- up is required in LMICs to strengthen health system 
capabilities, but adequate financing for this expansion is 
lacking. This article explores the critical role of innovative 
financing in scaling up surgical care in LMICs. We locate 
surgical system financing by using a modified fiscal space 
analysis. Through an analysis of published studies and 
case studies on recent trends in the financing of global 
health systems, we provide a conceptual framework that 
could assist policy- makers in health systems to develop 
innovative financing strategies to mobilise additional 
investments for scale- up of surgical care in LMICs. This 
is the first time such an analysis has been applied to the 
funding of surgical care. Innovative financing in global 
surgery is an untapped potential funding source for 
expanding fiscal space for health systems and financing 
scale- up of surgical care in LMICs.
InTroduCTIon
In 2019, at the 74th United Nations (UN) 
General Assembly, the UN Member States 
recommitted to achieving Universal Health 
Coverage (UHC) for a healthier world 
by 2030.1 In 2015, the 68th World Health 
Assembly committed to strengthen surgery 
and anaesthesia care as a component of 
UHC.2 However, many low- income and 
middle- income countries (LMICs) are 
unable to provide universal access to safe, 
timely and affordable surgical care, including 
obstetric3 4 and anaesthesia3 for several 
reasons, including: low- quality surgical 
services,3 5 6 insufficient surgical workforce,7–9 
poor infrastructure10–12 and, importantly, 
weak governance and suboptimal organisa-
tion of health systems.13 14
In addition to weak governance and subop-
timal organisation of health systems,13 14 for 
LMICs, a major constraint to the provision of 
quality surgical care is inadequate financing.15 
In the context of diminishing Development 
Assistance for Health (DAH),16–18 constrained 
national budgets and competing health prior-
ities, new strategies are needed to expand 
fiscal space for health to finance scale- up 
of surgical services. Fiscal space refers to 
the ability of a government to increase 
overall public spending without compro-
mising macroeconomic stability.19 Innovative 
financing, which has been taken to scale in 
global health to finance AIDS, tuberculosis, 
malaria and vaccine- preventable diseases in 
summary box
 ► Inadequate funding of national surgical care pro-
grams restrains the expansion of quality surgical 
care in LMICs.
 ► Innovative financing has helped to fund numerous 
global health priorities at scale but is yet to be har-
nessed to fund surgical systems.
 ► The development of innovative financing instruments 
and mechanisms is an untapped funding source to 
expand the fiscal space for surgical care scale- up. 
It is also an opportunity to develop novel financing 
instruments based on the contextual specificities of 
a country, and region.
 ► We analyse published studies and recent trends in 
health system financing, together with successful 
innovative financing case studies to provide a con-
ceptual and interpretive framework. The framework 
could enable policymakers (and other relevant ac-
tors) to design, introduce and scale- up innovative 
financing mechanisms for surgical care in LMICs.
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Figure 1 The six domains of National Surgical, Obstetric and Anaesthesia Plans (NSOAPs) Source: Adapted from Citron et 
al.59 UHC, Universal Health Coverage.
LMICs,19–21 provides an opportunity for new and addi-
tional funding for scale- up of surgical care in LMICs.
Many LMICs have sought to strengthen their health 
systems by developing strategic plans—National Surgical, 
Obstetric and Anaesthesia Plans (NSOAPs)—explic-
itly designed to improve surgical care.22–25 Despite the 
specific intention of NSOAPs to help improve health 
system performance in LMICs26 and attain the UN 
Sustainable Development Goals,27 the potential impact 
of NSOAPs have been constrained by limited financing 
to support their implementation. To provide sustainable 
funding for NSOAPs and to effectively scale- up surgical 
care, a more systematic and comprehensive approach to 
financing is required.
This article explores the role of innovative financing 
in scaling up surgical care. We locate surgical system 
financing within a modified fiscal space analysis to 
explore strategies to increase funding for health systems. 
Based on an examination of the trends in health system 
financing and an evaluation of the cost of NSOAPs, we 
provide a conceptual framework that could be useful for 
policymakers in LMICs to mobilise additional financial 
investment for surgical systems.
FINANCINg The exPANSIoN oF SuRgICAL CARe IN LMICS
national surgical, obstetric and anaesthesia plans
NSOAPs are strategic plans embedded within country 
National Health Plans that aim to improve surgical care. 
In 2015, the Lancet Commission on Global Surgery, 
recommended an NSOAP framework (figure 1) that 
countries could use to improve surgical care.26 NSOAPs 
are an example of a complex health policy innovation that 
involves multiple stakeholders and interrelated elements 
of a health system.28 NSOAP implementation produces 
many changes at all levels and within all functional- 
domains of the health system; involves multiple stake-
holders with diverse interests working together towards 
a common goal of improving surgical care, and disrupts 
the established institutional logic29 within surgical 
provider groups and promotes new ways of functioning. 
Complex innovations require consistent leadership and 
a well- coordinated process for implementation, in which 
financing reform is approached in an integrated fashion, 
alongside other functional modifications in a health 
system.30 The NSOAP framework addresses this chal-
lenge by utilising a ‘systems’ approach to the implemen-
tation process: changes in financing are considered in 
terms of other elements of a health system—for example, 
service delivery, workforce, infrastructure, information 
management, finance and governance—to provide a 
unified and integrated approach to improving surgical 
care in a country.
Since 2015, several countries have developed and 
begun implementing NSOAPs as a means to improve 
surgical care and to simultaneously strengthen health 
systems.12 31–35 In addition to country- level activities, 
there are regional initiatives to improve surgical care 
worldwide.36
Without a financing strategy, however, the development 
and implementation of NSOAPs will be restrained. Expe-
rience to date suggests that the cost of implementing 
NSOAPs range from US$69.7 million in Rwanda32 to 
US$16.8 billion in Nigeria.34 The Tanzanian NSOAP is 
estimated to cost an additional US$1.51 per capita per 
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Table 1 Current NSOAP and their costs of implementation
Country
GDP per capita 
(World Bank 
2017)
Population
(World Bank, 
2018)
NSOAP 
years
Total NSOAP 
cost
NSOAP cost 
per year per 
capita
NSOAP cost/cap 
as a percentage of 
GDP/cap
NSOAP cost/cap as a 
percentage of health 
spending/cap
Zambia US$1509.80 17.3 million 5 years US$314 million US$3.62 0.24 6.49
Tanzania US$936.33 56.3 million 7 years US$597 million US$1.51 0.16 4.20
Rwanda US$748.39 12.3 million 6 years US$69.7 million US$0.94 0.13 1.98
Nigeria US$1968.56 195.9 million 5 years US$6.8 billion US$17.12 0.87 22.18
Source: Jumbam et al.15
GDP, gross domestic product; NSOAP, National Surgical, Obstetric and Anaesthesia Plans.
Figure 2 Health focus areas for DAH: 1990–2018 Source: Financing Global Health (No changes).60 DAH, Development 
Assistance for Health.
year annualised over a 7- year implementation phase, 
on top of the US$35.5 per capita annual spending on 
health.15 33 37
Though NSOAPs are fully costed (table 1), there 
are few, if any, financial commitments from domestic, 
external or private sources for their implementation. 
If a country cannot finance an NSOAP, it is unlikely to 
implement it—a major obstacle to scaling up surgical 
care globally.
Financing surgical systems
Financial investment in surgical care is very low at global 
and national levels.26 38 In LMICs, the sources of health 
system financing include government spending, private 
insurance and out- of- pocket expenditure at the national 
level, and DAH from international sources.
Globally, in 2018, the majority of the US$38.9 billion in 
DAH was allocated to infectious diseases (US$15.1 billion; 
39%), child health and maternal health (US$12.4 billion; 
32%) and health system strengthening (US$5.4 billion; 
14%). Non- communicable diseases (chronic diseases, 
injuries and cancers), under which many surgical- related 
conditions are categorised, accounted for US$0.78 billion, 
approximately 2% of DAH (figure 2). Since 2010, DAH 
has not increased substantially: the annual DAH growth 
rate of 4.6% in the 1990s fell to 1.8% between 2010 
and 2016.16 This decline is likely related to the global 
economic recession that began in 2008, which primarily 
affected donor countries and led them to encourage 
recipient countries to increase domestic spending and 
reduce dependence on external financing.39 Given the 
current uncertainty in both the global economic and 
political outlook, further growth in DAH is unlikely to 
increase substantially in the near future.
Many LMICs lack domestic resources to increase 
healthcare spending, where governments need to 
address multiple, competing development priorities 
simultaneously in uncertain political and economic 
contexts. As a result, many LMICs are unable to expand 
domestic health spending sufficiently and are dependent 
on DAH. In 2016, among countries in sub- Saharan Africa 
alone, external sources constituted more than one- third 
of the total health expenditure (THE) in 15 countries 
(figure 3).40 In South Africa, the second- largest economy 
in Africa, THE constituted 8.11%37 of gross domestic 
product, one of the highest in the African continent and 
13.5%41 of the total government expenditure, but below 
the recommended target of 15% of government budget 
established by the African Union Members States in the 
Abuja Declaration.42 In Nigeria, Africa’s largest economic 
nation, the health budget approximated 3.57% of the 
national fiscus in 2019, well below the target established 
by the Abuja Declaration.43
Given the decline in DAH and inadequate government 
contributions to health from traditional budget sources, 
national governments will need alternative sources of 
financing and imaginative strategies to increase domestic 
funding for health. Indeed, it may be challenging to 
scale- up essential healthcare interventions (eg, compre-
hensive HIV care), given the constrained fiscal envi-
ronments that characterise LMICs, without mobilising 
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Figure 3 DAH percentage of total health expenditure for 
southern African countries. Source: financing global health.60 
DAH, Development Assistance for Health.
Figure 4 Value chain framework for innovative financing Source: Adapted from Atun et al.47
investment using innovative strategies.44 So: how can 
governments in LMICs increase funding for healthcare 
through new funding strategies?
INNovATIve FINANCINg MeChANISMS
Innovative financing
Though varied definitions of innovative financing 
exist,45–48 it can best be described by contrasting it with 
traditional forms of health financing. The latter refers 
to a combination of three streams of funding for health 
systems: state (public), private (user out of pocket fees 
and private health insurance), and external entities 
(DAH). With traditional financing, monetary commit-
ments are typically linked to health system inputs (eg, 
human resources, infrastructure, medicines) or outputs 
such as health services. By contrast, innovative financing 
comes from new sources that are different from tradi-
tional finance and is intrinsically linked with creating 
higher value in health system performance (improved 
population health, financial protection and patient satis-
faction, with higher efficiency). Innovative financing 
involves novel sources of funding and new strategies for 
pooling funds, as well as the use of market mechanisms 
and incentives to improve the performance of funded 
programmes.47 It is thus the manner in which funds are 
mobilised, pooled and allocated to produce greater value 
in health system performance that distinguishes innova-
tive financing over the traditional form.47
The value chain approach provides a useful frame-
work to describe innovative financing (figure 4). By 
tracking the transformation of funds—mobilisation, 
pooling, channelling, allocation and implementation—it 
is possible to explore how innovation occurs at various 
steps of the value chain to improve the production of 
particular health services and enhance overall system 
performance (see box 1). Innovation in this context is 
conceived as any new idea, thing, practice or institutional 
arrangement that is perceived as novel to the system.49
Innovative financing for global health
Several innovative financing instruments (IFIs) have 
been effectively deployed and scaled- up for funding 
global health activities (box 2, table 2).19 Some of these 
instruments could be adapted and used to finance 
surgical systems. IFI’s ‘innovate’ in terms of how funds 
are mobilised, while innovative financing mechanisms, 
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box 1 Financing value chain in an innovative financing 
mechanism
We can illustrate the functioning of the value chain in an innovative 
financing mechanism that has reached a global scale: The global Fund 
to Fight AIDS, Tuberculosis, and Malaria (global Fund). The global Fund 
mobilises funds from several sources: bilateral funding mainly from 
donor governments, but also from private foundations such as the Bill 
& Melinda gates Foundation, private corporations and philanthropic 
organisations.47 Importantly, it can expand resource mobilisation from 
non- traditional sources using innovative financing instruments, such 
as Product (ReD) and debt swaps, which are discussed below.19 For 
the year 2018, the global Fund was able to mobilise uS$6.8 billion of 
funding to allocate to the programmes it supports.61 These resources 
are pooled and channelled through a dual- track financing approach 
that entails disbursing funds to both governments and local non- 
governmental organisations for programme implementation. emphasis 
is placed on accountable governance; decisions to channel funds are 
determined by an interdisciplinary review panel that involves a broad 
range of stakeholders, including patient advocacy groups—a group 
excluded from health planning and decision- making processes. Funds 
are allocated to hIv/AIDS, tuberculosis and malaria programmes, 
and for health system strengthening.62 Finally, implementation is 
supported through performance- based funding with incentives that 
encourage the achievement of programmatic goals with a transparent 
reporting process.
box 2 Innovative financing instruments
Voluntary solidarity Levy: unitaid
In 2006, unitaid was established to create favourable market 
dynamics for expanded access to medicines at scale to combat the 
three pandemics affecting low- income and middle- income countries 
(LMICs), namely hIv/AIDS, tuberculosis and malaria. While some of 
unitaid’s funding comes from donor governments as Development 
Assistance for health and from large foundations, the majority of its 
revenue is sourced from a small levy placed on airline tickets sold in 
several countries. This levy, which is small enough per ticket to be 
undiscernible to airline customers, has served to create a sustainable 
revenue stream for unitaid’s operations through the participation of 
LMICs and high- income countries. The revenues from the airline levy 
have been more predictable and consistent than the funding streams 
based on government grants and fundraising cycles and have enabled 
unitaid to mobilise more than one billion euros between 2006 and 
2013.
Voluntary contribution: ProduCT (rEd)
In 2006, Bono and Bobby Shriver launched ‘(ReD)’ to raise money 
for the global Fund to tackle hIv/AIDS in eight African countries.63 
(ReD), also known as ‘PRoDuCT(ReD)’, seeks to raise money from the 
private sector and raise public awareness of hIv/AIDS by partnering 
with large global brands, including Apple, Air Asia, Bank of America, 
Amazon, Durex, Nike and Starbucks to create (ReD) branded products. 
every purchase of a (ReD) branded product activates a corporate 
contribution to the global Fund. (ReD) seeks to use private sector 
partnerships to raise money for the global Fund and to increase 
awareness of the global Fund’s efforts to reduce the hIv/AIDS 
burden in Africa.64 Between 2006 and 2018, (ReD) raised more than 
uS$600 million of funding for the global Fund.63
Performance- based instruments: GAVI
In 2009, the British, Canadian Italian, Norwegian and Russian 
governments, and the Bill & Melinda gates Foundation, funded 
an Advance Market Commitment (AMC) to reduce the impact of 
pneumococcal disease on children in LMICs65 The purpose of the AMC 
is to incentivise vaccine manufacturers to develop vaccines tailored 
to the specific needs of LMICs and scale- up manufacturing of these 
new vaccines by guaranteeing an initial purchase price and quantity 
of vaccines for purchase. With the pre- established commitment for 
volumes and predictable pricing, the pneumococcal AMC was able to 
attract manufacturers to develop vaccines that might not otherwise be 
available. AMC has enabled the development of new pneumococcal 
vaccines that were funded by gAvI to enable eligible LMICs to 
immunise 149 million children by 2017, resulting in the prevention of 
655 000 deaths by 2020.65
bonds and securities: International Finance Facility 
for Immunisation, and The Children’s Investment Fund 
Foundation (CIFF):
gAvI, the vaccine Alliance (formerly the global Alliance for vaccines 
and Immunisation), was created to expand access to immunizations 
for children in LMICs.66 In 2006, the International Finance Facility 
for Immunisation (IFFIm) was established to access capital markets 
to mobilise funding for new vaccines and to ‘frontload’ funding to 
rapidly scale- up immunisation programmes in LMICs. IFFIm leverages 
long- term donor commitments to issue ‘vaccine Bonds’ on the public 
market to finance its operations.66 To pay interest on these bonds, 
IFFIm secures long- term (20–30 year) contribution ‘commitments’ 
or ‘pledges’ from governments that are contributed in instalments 
Continued
which integrate all elements of the financing value 
chain, pool, channel, allocate funds and improve the 
performance of implementing entities to achieve more 
significant impact through the use of incentives. Innova-
tive mechanisms expand the pool of funding through a 
combination of IFI’s and traditional sources of financing. 
Thus, while IFI’s help to mobilise funds that might be 
otherwise unavailable for health spending, Innovative 
Financing Mechanisms transform these funds in novel 
ways to generate higher value for health systems.
We discuss IFI’s that have mobilised funding in 
different manners to expand fiscal space for health 
systems in LMICs, for infectious diseases (HIV/AIDS, 
tuberculosis and malaria), maternal and child health 
(vaccinations) and environmental health (climate 
change).50 These IFI’s can be grouped into four broad 
categories (table 3) that include voluntary solidarity 
levies (Unitaid/Airline Levy), voluntary contributions 
(PRODUCT(RED)), performance- based instruments 
(Advanced Market Commitments), and bonds and other 
securities (GAVI bonds, Children’s Investment Fund 
Foundation (CIFF)).50
InnoVATIVE FInAnCInG For surGICAL sysTEms
situating innovative mechanisms within health system 
financing processes
How can governments and global entities use IFIs and 
mechanisms to increase funding for scale- up of surgical 
programmes in LMICs? A framework is needed to unify 
innovative financing practices within the broader health 
6 Reddy CL, et al. BMJ Global Health 2020;5:e002375. doi:10.1136/bmjgh-2020-002375
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box 2 Continued
over time, as governments are subject to their own budget rules that 
prevent them from allocating funding beyond a few years and in many 
cases, such as the uSA to an annual budgeting and appropriation 
process. These long- term commitments create a predictable funding 
stream that can be used to guarantee and pay off bonds that IFFIm 
issues in capital markets. The funding that is mobilised from bond 
issuance provides large amounts of upfront capital that can be used to 
frontload immunisation programmes to accelerate access. Through its 
vaccine Bonds, IFFIm has mobilised more than uS$6.0 billion in funds 
for gAvI .16 67
The CIFF is an independent, privately funded philanthropic 
organisation based in the uK whose mission is to transform the 
lives of poor and vulnerable children.68 CIFF functions as a private 
investment fund, similar to an endowment, with a diverse investment 
portfolio that aims to achieve a 6% annual rate of return (over a 
10- year basis) to support philanthropic activities through annual 
grant disbursements that total 5% of its fund.68 This arrangement 
has enabled CIFF to continue to grow while still making annual 
contributions to projects in line with CIFF’s mission. CIFF has also 
committed to responsible investments and limits investment in 
companies that do not align with its mission, such as tobacco 
and fossil fuel companies,69 and those that do not commit to the 
International Code of Marketing Breast- Milk Substitutes.68 In 2017, 
CIFF had uS$5.2 billion endowment under management, generated 
15.8% in net investment returns, and disbursed uS$208.3 million in 
grant funding to programmes focused on childhood and adolescence 
(uS$139 million), climate change (uS$65 million) and child protection 
(uS$6 million).70
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system financing processes. An approach using fiscal 
space analysis provides the basis for such a framework.
First defined by Heller, fiscal space refers to the ability 
of a government to increase overall public spending 
without compromising macroeconomic stability.51 In 
2010, Tandon and Cashin adapted the fiscal space anal-
ysis approach to the health sector.52 We modified the 
fiscal space approach to include innovative financing 
(table 3). The purpose of using fiscal space analysis is to 
provide a systematic means for policy- makers to evaluate 
potential funding sources for the health sector in general 
and to identify new sources of funding for implementa-
tion of an NSOAP.
Fiscal space analysis has been used in several countries 
to both determine new funding sources, and evaluate 
existing strategies to increase health sector spending,53 54 
but no country has yet considered in this analysis inno-
vative financing as a potential source of funding. A 
modified fiscal space analysis should include innova-
tive financing together with the five ‘typical’ sources or 
drivers, of resource mobilisation in a country: (1) macro-
economic conditions; (2) government budget allocated 
to the health sector; (3) allocation of health sector- 
specific resources; (4) improved health system efficiency 
and (5) funding from external sources.
General tax revenues or health promoting taxes (eg, 
tobacco and alcohol tax) or removal of ineffective 
global energy subsidies would be useful new sources 
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Table 3 Components of fiscal space
Fiscal space pillar Explanation and example
1. Macroeconomic conditions Increased GDP growth
For example, sustained economic growth in Turkey, from 2000 to 2008, allowed the 
government to increase public sector funding for health at an average annual growth rate of 
9.1%, paving the way for UHC scale- up.71
2. Reprioritisation of 
government budget
Increased health budget as a proportion of national fiscus
For example, Increasing country health budgets to 15% of the national GDP in African nations, 
as outlined by the Abuja Declaration.42
3. Health sector- specific 
resources
Sugar- tax to finance diabetic screening at primary healthcare level
For example, Introducing excise taxes on specific goods or purchases such as tobacco,72 
alcohol73 or sugar and reducing emergency subsidies.74
4. Efficiency of existing 
resources
Evaluation of National Health Accounts to identify and reduce wasteful expenditure
Improving both technical and allocative efficiency could provide an efficiency gain of up to 
US$8 per capita.75
5. External sources Increase funding from bilateral organisations
For example, the United States Agency for International Development (USAID) channelled 
US$27.2 million to The Human Resources for Health programme in Rwanda, which allowed the 
country to rapidly increase physicians needed to delivery Universal Health Coverage.76
6. Innovative financing Global Fund financing of antiretrovirals to support a National HIV/AIDS programme
For example, US$ 973 395 559 disbursed to South Africa helped to provide anti- retroviral's to 
4.35 million people with HIV/AIDS77
Source: Adapted from Tandon and Cashin52.
GDP, gross domestic product; UHC, Universal Health Coverage.
Figure 5 Framework for innovative financing and surgical systems. Source: original.
of financing, and have been used in LMICs and could 
provide additional revenues for the government.55 56 
Innovative financing would complement such taxes to 
generate new and additional sources of funds. An assess-
ment and optimisation of all funding sources, together 
with a plan to generate additional funds from innova-
tive financing, could provide countries with a compre-
hensive strategy to explore potential sources of funding 
to finance NSOAPs.
developing an innovative financing strategy
The proposed framework (figure 5) consists of three 
components: the ‘drivers of health system spending’ or 
fiscal space, the innovative financing strategy, and the 
surgical system. The surgical system exists within the 
broader health system—a dynamically complex envi-
ronment49 that consists of multiple actors, a constantly 
evolving context and non- linear cause–effect relation-
ships.49 The innovative financing strategy is influenced 
in both directions—by the health system and the fiscal 
space—which, in turn, shape the innovative financing 
value chain. Each component of the value chain inter-
acts with others. The five drivers of fiscal space are 
co- dependent and relational. The health budget cannot 
increase without macroeconomic growth. Macroe-
conomic growth will not occur without the efficient 
allocation of resources by a government. Further, the 
degree to which innovative financing attains surgical 
system goals, will in turn, influence subsequent fiscal 
space analyses, the feasibility of mobilising additional 
investment and future innovative financing strategies. 
Thus, the nature of the interaction between value chain 
elements in relation to fiscal space, surgical system and 
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the broader health system, determines the extent to 
which value increases. When designing new innovative 
financing mechanisms, the organising principle should 
be that of maximising value defined by the surgical 
system.
For the proposed framework to be useful, two areas 
must be addressed: (1) who will use the framework? 
and: (2) how will they use it? At a national level, govern-
ments could use the framework to design specific and 
contextually relevant, innovative financing strategies 
for NSOAP financing. This would entail a collaborative 
effort between relevant parts of government—minis-
tries of health or finance, for example—working with 
academia or non- governmental organisations to design 
innovative strategies for the domestic setting. However, 
development banks (eg, African Development Bank), 
regional entities (eg, Southern African Development 
Community), philanthropic bodies, non- governmental 
organisations, and the private sector could apply this 
methodology to support individual countries, or 
country blocs, to fund scale- up of surgical care. This 
means carefully constructing all aspects of the value 
chain and creating inclusive governance and account-
ability mechanisms to attain surgical system goals: 
health outcomes, financial risk protection and patient 
satisfaction.
The first step, resource mobilisation, can be 
approached with different tactics and stakeholders in 
mind, from microlevies introduced by governments to 
impact investing by the private sector entities. Bilateral 
and multilateral agencies, philanthropic foundations, 
non- governmental organisations and private compa-
nies could all play a role in this step. It is important 
that the contributions of all possible stakeholders are 
pooled for maximum impact, without restrictive indi-
vidual stipulations on the use of the mobilised funds. 
The mobilised funds could be channelled at an amount 
appropriate for the breadth and scope of the planned 
scale- up: at global, regional, national and subnational 
levels. Allocation of the available funds could be 
targeted at specific priority areas, for example, UHC 
packages aimed at addressing the essential surgery 
components laid out by the Disease Control Priorities 
third Edition,57 supporting current country commit-
ments by funding achievement of regional targets, such 
as the Cape Town Declaration on Rheumatic Heart 
Disease,58 or advancing the NSOAP pillars. It is essen-
tial that funding is allocated to specific interventions 
that consist of a core set of measurable and feasible 
(factoring in the specificity of the context) activities at 
a given cost. This will help calculate the contours of 
Return on Investment, required to attract additional 
funding and promote confidence in implementing 
bodies that surgery is a worthy investment with posi-
tive, measurable health and economic outcomes, over 
a finite period, and at a specific cost. Such funding 
may be performance enhancing, for instance, to 
implement NSOAPs based on specific criteria (eg, 
consistent leadership, alignment of professional soci-
eties and involvement of civil society), technical assis-
tance provided by a local non- governmental/civil 
society organisation or for providing incentives that 
encourage collaboration and accountability between 
implementers.
ConCLusIon
Innovative financing is a novel approach for providing 
new and additional funding for global health. This 
paper highlights some examples of innovative financing 
that have attained scale in global health. NSOAPs are 
cost- effective complex health system innovations that 
require sustained funding over many years. Changing 
trends in DAH, coupled with constrained national 
budgets, means a systematic approach to increasing 
and sustaining health system financing is necessary. 
Innovative financing could help expand available funds 
for NSOAP implementation to scale up surgical care 
while strengthening health systems for better health 
outcomes.
Author affiliations
1Program in global Surgery and Social Change, Department of global health and 
Social Medicine, harvard Medical School, Boston, Massachusetts, uSA
2Department of Plastic and oral Surgery, Boston Children's hospital, Boston, 
Massachusetts, uSA
3Department of Surgery, NewYork- Presbyterian hospital/Weill Cornell Medical 
Center, New York, New York, uSA
4Center for global Surgery evaluation, Massachusetts eye and ear Infirmary, 
Boston, Massachusetts, uSA
5Department of global health equity, Department of otology and Laryngology, 
harvard Medical School, Boston, Massachusetts, uSA
6global health and Population, harvard university T h Chan School of Public health, 
Boston, Massachusetts, uSA
7Department of global health and Social Medicine, harvard Medical School, Boston, 
Massachusetts, uSA
Twitter Ché L Reddy @CheLenReddy, Alexander W Peters @alexpeters, Desmond 
Tanko Jumbam @desmondtanko, John g Meara @JohnMeara and Rifat Atun 
@RifatAtun
Contributors CLR conceived the study. CLR, AWP, LC, DTJ and RA developed 
the manuscript and original analysis. RA, JM and BCA provided critical analysis 
and revision to the entire manuscript. All authors read and approved the final 
manuscript.
Funding The Program in global Surgery and Social Change receives funding from 
the ge Foundation as part of the SS2020 program and Blake Alkire has received 
funding from Mercy Ships, both unrelated to this manuscript.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement No additional data are available
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId ids
Ché L Reddy http:// orcid. org/ 0000- 0002- 8800- 7359
Desmond Tanko Jumbam http:// orcid. org/ 0000- 0002- 3062- 2519
Rifat Atun http:// orcid. org/ 0000- 0002- 1531- 5983
Reddy CL, et al. BMJ Global Health 2020;5:e002375. doi:10.1136/bmjgh-2020-002375 9
BMJ Global Health
REFERENCES
 1 Universal health coverage political Declaration, 2019. Available: 
https://www. un. org/ pga/ 73/ wp- content/ uploads/ sites/ 53/ 2019/ 05/ 
UHC- Political- Declaration- zero- draft. pdf
 2 68th World Health Assembly. WHA 68.15 strengthening emergency 
and essential surgical care and anaesthesia as a component of 
universal health coverage. Provisional Agenda Item 2015;51:16–18.
 3 Bishop D, Dyer RA, Maswime S, et al. Maternal and neonatal 
outcomes after caesarean delivery in the African surgical outcomes 
study: a 7- day prospective observational cohort study. Lancet Glob 
Health 2019;7:e513–22.
 4 Alliance for Maternal and Newborn Health Improvement (AMANHI) 
mortality study group. Population- Based rates, timing, and causes 
of maternal deaths, stillbirths, and neonatal deaths in South Asia 
and sub- Saharan Africa: a multi- country prospective cohort study. 
Lancet Glob Health 2018;6:e1297–308.
 5 Biccard BM, Madiba TE, Kluyts H- L, et al. Perioperative patient 
outcomes in the African surgical outcomes study: a 7- day 
prospective observational cohort study. Lancet 2018;391:1589–98.
 6 Kruk ME, Gage AD, Arsenault C, et al. High- Quality health systems 
in the sustainable development goals era: time for a revolution. 
Lancet Glob Health 2018;6:e1196–252.
 7 Rayne S, Burger S, Straten SV, et al. Setting the research and 
implementation agenda for equitable access to surgical care in 
South Africa. BMJ Glob Health 2017;2:e000170.
 8 Dell AJ, Kahn D. Where are general surgeons located in South 
Africa? S Afr J Surg 2018;56:12–20.
 9 Holmer H, Lantz A, Kunjumen T, et al. Global distribution of 
surgeons, anaesthesiologists, and obstetricians. Lancet Glob Health 
2015;3 Suppl 2:S9–11.
 10 Dell AJ, Kahn D. Surgical resources in South Africa: a review of the 
number of functional operating theatres. S Afr J Surg 2018;56:2–8.
 11 Nyberger K, Jumbam DT, Dahm J, et al. The situation of safe surgery 
and anaesthesia in Tanzania: a systematic review. World J Surg 
2019;43:24–35.
 12 Burssa D, Teshome A, Iverson K, et al. Safe surgery for all: early 
lessons from implementing a national Government- Driven surgical 
plan in Ethiopia. World J Surg 2017;41:3038–45.
 13 Kickbusch I, Gleicher D. Governance for health in the 21st century. 
WHO, 2012: 1–106.
 14 Frenk J, Moon S. Governance challenges in global health. N Engl J 
Med 2013;368:936–42.
 15 Jumbam DT, Reddy CL, Roa L, et al. How much does it cost to scale 
up surgical systems in low- income and middle- income countries? 
BMJ Glob Health 2019;4:e001779.
 16 Dieleman J, Campbell M, Chapin A, et al. Evolution and patterns 
of global health financing 1995–2014: development assistance for 
health, and government, prepaid private, and out- of- pocket health 
spending in 184 countries. The Lancet 2017;389:1981–2004.
 17 Moon S, Omole O. Development assistance for health: critiques, 
proposals and prospects for change. Health Econ Policy Law 
2017;12:207–21.
 18 Institute for health metrics and evaluation. Available: http://www. 
healthdata. org/ institute- health- metrics- and- evaluation [Accessed 20 
Feb 2019].
 19 Atun R, Silva S, Knaul FM. Innovative financing instruments for 
global health 2002-15: a systematic analysis. Lancet Glob Health 
2017;5:e720–6.
 20 Hecht R, Palriwala A, Rao A. Innovative financing for global health: a 
moment for expanded us engagement? Cent Strateg Int Stud, 2010.
 21 Douste- Blazy P. Innovative financing for development. Rep LIFE 
Lead Innov Financ Equity, 2009.
 22 Citron I, Jumbam D, Dahm J, et al. Towards equitable surgical 
systems: development and outcomes of a national surgical, obstetric 
and anaesthesia plan in Tanzania. BMJ Glob Health 2019;4:e001282.
 23 Albutt K, Sonderman K, Citron I, et al. Healthcare leaders 
develop strategies for expanding national surgical, obstetric, and 
anaesthesia plans in who AFRO and EMRO regions. World J Surg 
2019;43:360–7.
 24 The Bulletin. Implementing World health assembly resolution 
68.15: national surgical, obstetric, and anesthesia strategic plan 
development—the Zambian experience, 2017. Available: http:// 
bulletin. facs. org/ 2017/ 06/ implementing- world- health- assembly- 
resolution- 68- 15/ [Accessed 19 Feb 2019].
 25 Siddiqui S, Vervoort D, Peters AW, et al. Closing the gap of children’s 
surgery in Pakistan. World Jnl Ped Surgery 2019;2:e000027.
 26 Meara JG, Leather AJM, Hagander L, et al. Global surgery 2030: 
evidence and solutions for achieving health, welfare, and economic 
development. The Lancet 2015;386:569–624.
 27 Roa L, Jumbam DT, Makasa E, et al. Global surgery and the 
sustainable development goals. Br J Surg 2019;106:e44–52.
 28 Atun R, de Jongh T, Secci F, et al. Integration of targeted health 
interventions into health systems: a conceptual framework for 
analysis. Health Policy Plan 2010;25:104–11.
 29 Kyratsis Y, Atun R, Phillips N, et al. Health systems in transition: 
professional identity work in the context of shifting institutional 
logics. Acad Manage J 2017;60:610–41.
 30 Atun RA, Menabde N, Saluvere K, et al. Introducing a complex 
health innovation—Primary health care reforms in Estonia 
(multimethods evaluation). Health Policy 2006;79:79–91.
 31 PGSSC. 2019 Dubai national surgical, obstetrics and anesthesia 
planning conference for who regional officers, high- level authorities, 
and Funders. Available: https://www. pgssc. org/ 2019- national- 
surgical- planning [Accessed 4 Apr 2019].
 32 Rwanda national, obstetric and anaesthesia plan: 2018-2024. 
Available: https:// docs. wixstatic. com/ ugd/ d9a674_ c5c3 6059 456a 
4164 80fd 58fd 553ef302. pdf
 33 Tanzania national surgical, obstetric and anaesthetic plan: 2018-
2025, 2018. Available: https:// docs. wixstatic. com/ ugd/ d9a674_ 4daa 
353b 7306 4f70 ab6a 53a9 6bb84ace. pdf
 34 Nigeria national, obstetric and anaesthesia plan: 2019-2023. 
Available: https:// docs. wixstatic. com/ ugd/ d9a674_ 1f7a a816 1c95 
4e2d bf23 7512 13bc6f52. pdf
 35 Surgical ZN. Zambian national surgical, obstetric, and anaesthesia 
strategic plan (NSOASP) year 2017-2021. Available: https:// docs. 
wixstatic. com/ ugd/ d9a674_ 70f6 813f e4e7 4c4d 99eb 0283 36a38745. 
pdf
 36 SADC secretariat. Media Statement - Joint Meeting of SADC 
Ministers of Health 2018, 2018. Available: https://www. sadc. int/ 
files/ 3315/ 4169/ 8409/ Media_ Statement_-_ Joint_ Meeting_ of_ SADC_ 
Ministers_ of_ Health_ and_ those_ responsible_ for_ HIV_ and_ AIDS_. 
pdf
 37 World bank open data. Available: https:// data. worldbank. org/ 
[Accessed 20 Feb 2019].
 38 Dieleman JL, Campbell M, Chapin A, et al. Future and potential 
spending on health 2015–40: development assistance for health, 
and government, prepaid private, and out- of- pocket health spending 
in 184 countries. The Lancet 2017;389:2005–30.
 39 Addis Ababa action agenda of the third International Conference on 
financing for development, 2015. Available: https://www. un. org/ esa/ 
ffd/ wp- content/ uploads/ 2015/ 08/ AAAA_ Outcome. pdf
 40 External health expenditure (% of current health expenditure). 
Available: https:// data. worldbank. org/ indicator/ SH. XPD. EHEX. CH. ZS 
[Accessed 18 May 2019].
 41 UNICEF. Health budget South Africa 2018/2018. Available: https://
www. unicef. org/ esaro/ UNICEF_ South_ Africa_-_ 2017_-_ Health_ 
Budget_ Brief. pdf [Accessed 17 Sep 2019].
 42 Abuja Declaration, 2001. Available: https://www. who. int/ 
healthsystems/ publications/ abuja_ report_ aug_ 2011. pdf? ua=1
 43 Breakdown of 2019 FGN Budget Proposal - Budget Office of the 
Federation - Federal Republic of Nigeria. Available: https://www. 
budgetoffice. gov. ng/ index. php/ breakdown- of- 2019- fgn- budget- 
proposal [Accessed 3 Oct 2019].
 44 Atun R, Chang AY, Ogbuoji O, et al. Long- Term financing needs for 
HIV control in sub- Saharan Africa in 2015-2050: a modelling study. 
BMJ Open 2016;6:e009656–9.
 45 Innovative Financing for Development: Scalable Business models 
that produce economic, Social, and environmental outcomes. 
Innovative financing initiative an initiative of the global development 
incubator, 2014.
 46 The World Bank. Innovative finance for development solutions: 
initiatives of the world bank group. Washington DC, USA: World 
Bank Group, 2009. http:// siteresources. worldbank. org/ CFPEXT/ 
Resources/ IF- for- Development- Solutions. pdf
 47 Atun R, Knaul FM, Akachi Y, et al. Innovative financing for health: 
what is truly innovative? Lancet 2012;380:2044–9.
 48 Gargasson JL, Salomé B. The role of innovative financing 
mechanisms for health, 2010.
 49 Atun R. Health systems, systems thinking and innovation. Health 
Policy Plan 2012;27 Suppl 4:iv4–8.
 50 Atun R. Innovative financing (B): UNITLIFE Rifat Atun and Gabriel 
Seidman 1, 2015: 1–19.
 51 Heller PS. Understanding fiscal space. This Policy Discuss Pap, 
2005: 19.
 52 Tandon A, Cashin C. Assessing public expenditure on health from 
a fiscal space perspective. Washington, DC: World Bank, 2010. 
http:// documents. worldbank. org/ curated/ en/ 333671468330890417/ 
Assessing- public- expenditure- on- health- from- a- fiscal- space- 
perspective
 53 Lane C. Rwanda: fiscal space for health and the MDGs revisited, 
2009.
10 Reddy CL, et al. BMJ Global Health 2020;5:e002375. doi:10.1136/bmjgh-2020-002375
BMJ Global Health
 54 Dijkstra A, Beckerman P, Dimitrova D, et al. Fiscal space profiles of 
countries in eastern and southern Africa: case study – Kenya fiscal 
space analysis, 2017.
 55 Jamison DT, Summers LH, Alleyne G, et al. Global health 2035: a 
world converging within a generation. Lancet 2013;382:1898–955.
 56 Verguet S, Gauvreau CL, Mishra S, et al. The consequences of 
tobacco tax on household health and finances in rich and poor 
smokers in China: an extended cost- effectiveness analysis. Lancet 
Glob Health 2015;3:e206–16.
 57 Gawande A, Debas HT, Donkor P, et al. Disease control priorities. 3rd 
Edn. Washington DC: World Bank Group, 2015.
 58 Zilla P, Bolman RM, Yacoub MH, et al. The Cape town Declaration on 
access to cardiac surgery in the developing world. Cardiovasc J Afr 
2018;29:256–9.
 59 Citron I, Sonderman K, Subi L, et al. Making a case for national 
surgery, obstetric, and anesthesia plans. Can J Anaesth 
2019;66:263–71.
 60 Financing Global Health. Institute for Health Metrics and Evaluation 
(IHME)Visualization Hub. Available: http:// vizhub. healthdata. org/ fgh 
[Accessed 4 Oct 2019].
 61 The global fund: 2018 annual financial report, 2018. Available: 
https://www. theglobalfund. org/ media/ 8470/ corporate_ 
2018annualfinancial_ report_ en. pdf
 62 Warren AE, Wyss K, Shakarishvili G, et al. Global health Initiative 
investments and health systems strengthening: a content analysis of 
global fund investments. Global Health 2013;9:30.
 63 The global fund: private and Nongovernment partners: (red). Available:  
https% 3a% 2f% 2fwww. theglobalfund. org% 2fen% 2fprivate- ngo- 
partners% 2fresource- mobilization% 2fred% 2f [Accessed 26 Apr 2019].
 64 The global fund Welcomes product red. Available:  https% 3a% 2f% 
2fwww. theglobalfund. org% 2fen% 2fnews% 2f2006- 01- 26- the- global- 
fund- welcomes- product- red% 2f [Accessed 26 Apr 2019].
 65 The Vaccine Alliance AS. 2017 Pneumococcal AMC Annual Report: 
1 January - 31 December 2017. Available: https://www. gavi. org/ 
library/ gavi- documents/ amc/ 2017- pneumococcal- amc- annual- 
report/
 66 About Gavi, the vaccine alliance. Available: https://www. gavi. org/ 
about/ [Accessed 26 Apr 2019].
 67 Overview - International Finance Facility for Immunisation. 
Available: https://www. iffim. org/ about/ overview/ [Accessed 23 Aug 
2019].
 68 Children’s Investment Fund Foundation, About Us, Endowment. 
Available: https:// ciff. org/ about- us/ endowment/ [Accessed 26 Apr 
2019].
 69 Larry Fink’s Letter to CEOs. BlackRock. Available: https://www. 
blackrock. com/ corporate/ investor- relations/ larry- fink- ceo- letter 
[Accessed 22 Jun 2019].
 70 Children’s Investment Fund Foundation Annual Report: 2017, 2019. 
Available: https:// ciff. org/ documents/ 828/ CIFF_ AnnualReport_ 2017. 
pdf
 71 Atun R, Aydın S, Chakraborty S, et al. Universal health coverage in 
turkey: enhancement of equity. Lancet 2013;382:65–99.
 72 Organisation mondiale de la santé. Who report on the global 
tobacco epidemic, 2015: raising taxes on tobacco, 2015.
 73 Sornpaisarn B. Resource tool on alcohol taxation and pricing 
policies, 2017.
 74 Taxes on sugary drinks: why do it? 2017. Available: https:// apps. 
who. int/ iris/ bitstream/ handle/ 10665/ 260253/ WHO- NMH- PND- 16. 
5Rev. 1- eng. pdf? sequence=1 [Accessed 17 Nov 2019].
 75 Barroy H, Sparkes S, Dale E. Assessing fiscal space for health in low 
and middle income countries: a review of the evidence, 2016.
 76 Binagwaho A, Kyamanywa P, Farmer PE, et al. The human resources 
for health program in Rwanda--new partnership. N Engl J Med 
2013;369:2054–9.
 77 South Africa - Results - The Global Fund Data Explorer. Available: 
https:// data. theglobalfund. org/ investments/ results/ ZAF [Accessed 
17 Nov 2019].
